Suven Life Sciences Ltd Share Price Suven Life Scie.

272.10

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)

273.00

Open ()
Turnover (lac)
Prev. Close ()
Day's Vol.(shares)
Detailed Quote

Corporate Action

Period From
Period To
Purpose AGM Date Announcement Date Book Closure Start Date Book Closure End Date
Board Meeting - 17-May-2019 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2019 ,inter alia, to consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2019 and related matters. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 25th May, 2019, has taken on record and approved the Audited Standalone and Consolidated Financial Results of the Company under Ind AS for the quarter and for the year ended 31st March, 2019 and approved the following matters. (As Per BSE Announcement Dated On 25/05/2019)
Board Meeting - 15-Apr-2019 - -
With reference to the above subject, please note that the Board of Directors of the company, at its meeting held today i.e. 15th April, 2019, has taken on record and approved the following matter(s). 1) Approved the enhancement of investment limits in WOS in USA Suven Neurosciences, Inc. from USD 25 Million upto USD 50 Million to undertake clinical trials on the molecules in the pipeline. 2) As per the policy approved by the Board, the information on the grant of product patents to the company and periodical updates thereon will be available henceforth on our Companys website only. Since grant of product patents per se is not material information to be notified hence the Company is discontinuing forthwith the issue of News Releases to the Stock Exchanges. With reference to the above subject, please note that the Board of Directors of the company, at its meeting held today i.e. 15th April, 2019, has taken on record and approved the following matter(s). ? Approved the amended the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI) and Policy on determination of legitimate purpose in pursuance to the SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018. The amended code is effective from April 1,2019 and uploaded on our companys website
Board Meeting - 04-Mar-2019 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/03/2019 ,inter alia, to consider and approve With reference to above subject, pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of Board of Directors of our Company will be held on Saturday, the 9th March, 2019 at 12:00 Noon at the Registered Office, SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad, Telangana, India - 500034, to consider inter alia, and take on record the following matter(s): To consider and approve the investments in new overseas subsidiary and other matters, if any. Please further note that TRADING WINDOW for dealing in the securities of the company is closed from 5th March, 2019 to 11th March, 2019 (both days inclusive) as per PIT Code of the Company. Trading window will be opened from 12th March, 2019. 1. Approved the creation of Wholly Owned Subsidiary (WOS) Suven Pharma, Inc a Delaware Company in USA under CRAMS Division. 2. Approved investment of 75 Mn USD in the said WOS for new business opportunities and acquisitions etc., (As Per BSE Announcement Dated 09.03.2019)
Board Meeting - 29-Jan-2019 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2019 ,inter alia, to consider and approve 1) To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended 31st December, 2018 2) To consider declaration of Interim Dividend, if any, for the financial year 2018-19 and related matters etc. and 3) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to eligible shareholders would be 15th February, 2019, if considered and approved by the Board. Please further note that TRADING WINDOW for dealing in the securities of the company is closed from 28th January, 2019 to 8th February, 2019 (both days inclusive) as per PIT Code of the Company. Trading window will be opened from 9th February, 2019. 1) To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended 31st December, 2018 2) To consider declaration of Interim Dividend, if any, for the financial year 2018-19 and related matters etc. and 3) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to eligible shareholders would be 15th February, 2019, if considered and approved by the Board. Please further note that TRADING WINDOW for dealing in the securities of the company is closed from 28th January, 2019 to 8th February, 2019 (both days inclusive) as per PIT Code of the Company. Trading window will be opened from 9th February, 2019. Suven Life Sciences Ltd has informed BSE that a Meeting of Board of Directors of the Company will be held on February 05, 2019, inter alia, to consider and take on record the following matter(s): 1. To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended December 31, 2018. 2. To consider declaration of Interim Dividend, if any, for the financial year 2018-19 and related matters etc. Further, the TRADING WINDOW for dealing in the securities of the company is closed from January 28, 2019 to February 08, 2019 (both days inclusive) as per PIT Code of the Company. Trading window will be opened from February 09, 2019. Suven Life Sciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 05, 2019, inter alia, has declared an interim dividend of Rs. 1.50 per equity share of face value Rs. 1/- each for the year 2018-2019.The above said dividend will be paid on and from February 25, 2019. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 5th February, 2019, has taken on record the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended 31st December, 2018 and approved the following matters. Interim Dividend a) The Board declared an interim dividend of Rs. 1.50 per equity share of face value Rs 1/- each for the year 2018-2019. b) The Board approved the Record Date i.e., 15th February 2019 notified by the Company for the purpose of payment of interim dividend to the eligible shareholders. c) The above said dividend will be paid on and from 25th February, 2019. This is to inform you that the Board of Directors of the Company at their meetings held on 5th February 2019 approved the following: The Company has acquired all the shares of Suven Pharmaceuticals Limited (SPL), a public limited company, from its existing shareholders. Pursuant to which, Suven Pharmaceuticals Limited has become a wholly owned subsidiary of the Company. The Board also approved draft Scheme of Arrangement to be filed at the National Company Law Tribunal bench at Hyderabad, for necessary approvals. This is to inform you that the Board of Directors of the Company at their meetings held on 5th February 2019 approved the following: The Company has acquired all the shares of Suven Pharmaceuticals Limited (SPL), a public limited company, from its existing shareholders. Pursuant to which, Suven Pharmaceuticals Limited has become a wholly owned subsidiary of the Company. The Board also approved draft Scheme of Arrangement to be filed at the National Company Law Tribunal bench at Hyderabad, for necessary approvals. (As Per BSE Announcement Dated on 2/5/2019 6:25:35 PM)
Board Meeting - 06-Nov-2018 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2018 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Board Meeting of our Company will be held on Wednesday, the 14th November, 2018 at 11:30 a.m. at Park Hyatt Hyderabad, Road No. 2, Banjara Hills, Hyderabad, Telangana, India, 500034, to consider, among other things, inter alia, and take on record the following matters: ? To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and half-year ended September 30, 2018. Please further note that TRADING WINDOW for dealing in the securities of the company is closed from 06th November, 2018 to 18th November, 2018 (both days inclusive) as per PIT Code of the Company. Trading window will be opened from 19th November, 2018. Notification of Un-audited Financial Results for the quarter ended 30th September,2018 (As Per BSE Announcement Dated On 14/11/2018)
Board Meeting - 06-Aug-2018 - -
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2018 ,inter alias, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Board Meeting of our Company will be held on Tuesday, the 14th August, 2018 at 3:00 p.m. at the Registered Office, SDE Serene Chambers, 6th Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, among other things, inter alia, and take on record the following matters: ? To consider and approve the Un-audited Financial Results of the Company under Ind AS for the first quarter ended June 30, 2018. Please further note that TRADING WINDOW for dealing in the securities of the company is closed from 06th August, 2018 to 19th August, 2018 (both days inclusive) as per PIT Code of the Company. Trading window will be opened from 20th August, 2018. You are requested to take this notice on your record. With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. 14th August, 2018, has taken on record the Un-audited Financial Results of the Company under Ind AS for the quarter ended 30th June, 2018. We are enclosing herewith the following documents: a) Un-audited Financial Results under Ind AS for the quarter ended 30th June, 2018 b) Limited Review Report of Statutory Auditors of the Company We hereby notify that in terms of Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 our Company will submit standalone financial results for the financial year 2018-2019. Please find enclosed Press Release of our company. We request you to take these documents on your records. The Board Meeting commenced at 3:00 P.M. and concluded at 4:45 P.M. Notification of Un-audited Financial Results for the quarter ended 30th June, 2018 (As Per BSE Announcement Dated On 14/08/2018)